Pharmacovigilance and the Italian Medicines Agency

ABSTRACT

The new European Union (EU) regulations on pharmacovigilance require that the national systems are strengthened in order to fit the new requirements. The Italian Pharmacovigilance System, coordinated by the Italian Medicines Agency (AIFA), is made by local and regional structures. In 2007, a program for funding active pharmacovigilance projects in the Italian Regions was established by the National law. The AIFA is responsible for the preparation of guidelines aimed at the identification of research areas and for the approval of the projects submitted by the regions. In April 2012, the AIFA started a program of visits at the regional pharmacovigilance centers (RPCs), aimed at monitoring their performances, evaluating the quality of the activities in order to understand the main differences and discrepancies and with a view to start a program of harmonization of the procedures in place. The outcome of the visits program highlighted major differences among the quality management systems of the various centers; hence, AIFA has decided to launch an initiative to promote in the next months the harmonization of procedures. The synergy among AIFA, regional structures, RPCs, and local structure responsible for pharmacovigilance is needed in order to establish a robust pharmacovigilance system working in full compliance with the provisions of the new EU legislation.

KEYWORDS

• Italian Medicines Agency
• AIFA
• Italian Pharmacovigilance System
• pharmacovigilance

Showing references and in-text citations exactly as published.

• DOI10.4103/0976-500X.120940Copy

RELATED ARTICLES

Matched on section and article type within this issue of JPP.

• Article · VOLUME 4, ISSUE 4SInformatics applied to pharmacovigilance: Future perspectivesMichele Menniti, Annamaria Menniti, Marinella Patanè, Stefania Esposito, Chiara Giofrè, Rossana Aiello, Emilio Russo · pp. S43–S44CommentarySame type: Article
• Article · VOLUME 4, ISSUE 4SLimitations and obstacles of the spontaneous adverse drugs reactions reporting: Two “challenging” case reportsCaterina Palleria, Christian Leporini, Serafina Chimirri, Giuseppina Marrazzo, Sabrina Sacchetta, Lucrezia Bruno, Rosaria M. Lista, Orietta Staltari, Antonio Scuteri, Francesca Scicchitano, Emilio Russo · pp. S66–S67CommentarySame type: Article
• Article · VOLUME 4, ISSUE 4SAbatacept in psoriatic arthritis: Case report and short reviewFrancesco Ursini, Saverio Naty, Emilio Russo, Rosa Daniela Grembiale · pp. S29–S30Same type: Article
• Article · VOLUME 4, ISSUE 4SAnti-vascular endothelial growth factor drugs safety and efficacy in ophthalmic diseasesPasquale Ventrice, Christian Leporini, Jose’ Francisco Aloe, Ettore Greco, Giacomo Leuzzi, Giuseppina Marrazzo, Giovanni Battista Scorcia, Donatella Bruzzichesi, Varano Nicola, Vincenzo Scorcia · pp. S38–S39Same type: Article